Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Several mobile phones and a quantity of cash was seized from the two men. When police arrived at the property, a golf ball ...

Certain cancers and Parkinson's disease are especially difficult to treat ... The FFG Austrian Life Science project "Seek & ...

KinCon biolabs, a spin-off from the University of Innsbruck, is expanding its patented platform technology to support ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...